Glaxosmithkline Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹938cr+16.6% on Q1 FY26
Net profit
₹237cr+15.7% on Q1 FY26
EBITDA margin
31.5%+0.3 pts on Q1 FY26
EPS
₹14.00+15.7% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue938805+16.6%
EBITDA296251+17.6%
EBITDA margin31.5%31.2%+0.3 pts
Profit before tax322279+15.6%
Net profit237205+15.7%
EPS₹14.00₹12.10+15.7%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹938 crNet profit₹237 crNet margin25.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
42,319————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2,4932,4931,657877553
17.317.30.00.00.0
39,843————
3,9553,8223,7493,4543,252
—+1.9%+8.6%+6.2%—
1,3541,3091,177909804
34.2%34.3%31.4%26.3%24.7%
1,2871,2431,111839739
1,0681,036928590611
27.0%27.1%24.7%17.1%18.8%
₹63.05₹61.15₹54.75₹34.82₹36.05
—+11.7%+57.2%−3.4%—
—9031,290582484
—−55.3−23.0−31.2−44.0
8488481,267551440
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAXO₹2,498.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹42,319 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————42,318.6
- Cash, Equiv & ST Investments553.2877.41,657.12,493.02,493.0
+ Minority Interest0.00.00.017.317.3
Enterprise Value————39,842.9
Revenue3,251.73,453.73,749.23,821.73,954.9
Growth %, YoY—+6.2+8.6+1.9—
EBITDA804.3908.71,177.41,309.21,353.5
Margin %24.7326.3131.4034.2634.22
EBIT738.5839.01,110.61,242.81,286.7
Net Income610.7590.0927.61,036.01,068.2
Margin %18.7817.0824.7427.1127.01
EPS, Adj (current shares)36.0534.8254.7561.1563.05
Growth %, YoY—-3.4+57.2+11.7—
Cash from Operations484.2582.01,289.9903.3—
Capital Expenditures-44.0-31.2-23.0-55.3—
Free Cash Flow440.2550.81,266.9848.0848.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Glaxosmithkline Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Glaxosmithkline Pharmaceuticals (NSE: GLAXO) had a market capitalisation of ₹42,608 crore at the 29 October 2026 close (₹2,515.10 a share), a PE ratio of 39.9 on the last four quarters' profit and a price-to-book ratio of 18.79. In FY26 its consolidated net profit was ₹1,036 crore on revenue of ₹3,822 crore; in Q1 FY27 (April–June 2026) it was ₹237 crore, up 15.7% year on year. It had no borrowings on 31 March 2026. Promoters held 75.00% of the shares on 30 September 2026.

Share price used
₹2,515.10 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Glaxosmithkline Pharmaceuticals at a glance · consolidated

Market cap
₹42,608 Crat ₹2,515.10 · 29 Oct close
PE ratio (last 4 quarters)
39.941.1 on FY26 profit
Price to book (PB)
18.79book value ₹133.84 a share
ROE (FY26)
49.1%−0.6 pts vs FY25ROCE 52.4%
Debt to equity
0.00net cash ₹2,782 Cr
Promoter holding
75.00%unchanged vs 30 Jun 202630 September 2026
Dividend yield
2.27%₹57 a share in 12 months
Net worth
₹2,267 Cr+16.2% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹848 Cr−33.1% vs FY25

Questions

What is the Glaxosmithkline Pharmaceuticals PE ratio today?

Glaxosmithkline Pharmaceuticals' PE ratio is 39.9 at the 29 October 2026 close (₹2,515.10 a share): a market capitalisation of ₹42,608 crore divided by consolidated net profit of ₹1,068 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹1,036 crore) it is 41.1.

What is the Glaxosmithkline Pharmaceuticals PB ratio (price to book value)?

Glaxosmithkline Pharmaceuticals' price-to-book (PB) ratio is 18.79 at the 29 October 2026 close: a market capitalisation of ₹42,608 crore divided by shareholders' equity (book value) of ₹2,267 crore on 31 March 2026. That is a book value of ₹133.84 per share against a share price of ₹2,515.10.

What is the Glaxosmithkline Pharmaceuticals net worth?

Glaxosmithkline Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹2,267 crore on 31 March 2026, up 16.2% from ₹1,951 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹42,608 crore at the 29 October 2026 close.

What is the Glaxosmithkline Pharmaceuticals market cap?

Glaxosmithkline Pharmaceuticals' market capitalisation was ₹42,608 crore at the 29 October 2026 close: 16.94 crore shares at ₹2,515.10 each.

Is Glaxosmithkline Pharmaceuticals debt free?

Yes. Glaxosmithkline Pharmaceuticals had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹2,782 crore of cash, bank balances and current investments.

What is the Glaxosmithkline Pharmaceuticals debt to equity ratio?

Glaxosmithkline Pharmaceuticals' debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹2,285 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Glaxosmithkline Pharmaceuticals ROE and ROCE?

In FY26, Glaxosmithkline Pharmaceuticals' return on equity (ROE) was 49.1% and its return on capital employed (ROCE) was 52.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 49.8% and ROCE 52.5%.

What is the Glaxosmithkline Pharmaceuticals book value per share?

Glaxosmithkline Pharmaceuticals' book value per share was ₹133.84 on 31 March 2026: shareholders' equity of ₹2,267 crore divided by the 16.94 crore shares in issue, up 16.2% from ₹115.18 a year earlier. The share price at the 29 October 2026 close was ₹2,515.10.

What is the Glaxosmithkline Pharmaceuticals shareholding pattern?

On 30 September 2026, Glaxosmithkline Pharmaceuticals' shares were held by promoters 75.00%, foreign portfolio investors (FII/FPI) 4.75%, domestic institutions (DII) 8.48% (including mutual funds at 6.07%) and retail and other non-institutional investors 11.77%. Over the year, FII holding was down 0.05 percentage points from 4.80% and DII holding was up 0.73 percentage points from 7.75%.

What is the Glaxosmithkline Pharmaceuticals EPS?

Glaxosmithkline Pharmaceuticals' basic earnings per share (EPS) were ₹54.52 in FY26, against ₹54.52 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹62.01.

What is the Glaxosmithkline Pharmaceuticals promoter holding?

Promoters held 75.00% of Glaxosmithkline Pharmaceuticals on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

When are the Glaxosmithkline Pharmaceuticals next results?

Glaxosmithkline Pharmaceuticals will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Glaxosmithkline Pharmaceuticals dividend yield?

Glaxosmithkline Pharmaceuticals' dividend yield is 2.27% at the 29 October 2026 close: dividends of ₹57 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹2,515.10. They were ₹57 on 29 May 2026.

What is the Glaxosmithkline Pharmaceuticals free cash flow?

In FY26, Glaxosmithkline Pharmaceuticals generated ₹903 crore of cash from operations and spent ₹55.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹848 crore. In FY25 it was ₹1,267 crore.

What are the Glaxosmithkline Pharmaceuticals latest quarterly results?

Glaxosmithkline Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 3 August 2026: consolidated net profit ₹237 crore, up 15.7% from ₹205 crore in Q1 FY26; revenue from operations ₹938 crore, up 16.6% year on year.

What is the Glaxosmithkline Pharmaceuticals dividend in 2026 and its record date?

In 2026, Glaxosmithkline Pharmaceuticals has declared one dividend: ₹57 with record date 29 May 2026.

What is the Glaxosmithkline Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Glaxosmithkline Pharmaceuticals' consolidated net profit was ₹1,036 crore, up 11.7% from ₹928 crore in FY25, on revenue from operations of ₹3,822 crore (up 1.9%). Over three years, from FY23, net profit was up 69.6%.

Glaxosmithkline Pharmaceuticals vs Pfizer: how do they compare?

In FY26, Glaxosmithkline Pharmaceuticals earned net profit of ₹1,036 crore on revenue of ₹3,822 crore, against ₹722 crore on ₹2,520 crore for Pfizer. Glaxosmithkline Pharmaceuticals' operating margin was 32.5% (Pfizer 33.6%) and its return on equity 49.1% (Pfizer 17.2%). At the 29 October 2026 close, Glaxosmithkline Pharmaceuticals' market capitalisation was ₹42,608 crore against ₹17,201 crore for Pfizer, and its PE ratio on FY26 profit 41.1 against 23.8.

How does Glaxosmithkline Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Pfizer, Abbott India and Global Health: Glaxosmithkline Pharmaceuticals' operating margin of 32.5% is the second highest of the four (Pfizer 33.6%, Abbott India 26.2%, Global Health 15.8%; peer average 25.2%); its return on equity of 49.1% is the highest of the four (Pfizer 17.2%, Abbott India 34.5%, Global Health 15.2%; peer average 22.3%); its revenue growth over three years of 5.5% a year is the third highest of the four (Pfizer 1.3% a year, Abbott India 9.0% a year, Global Health 17.9% a year; peer average 9.4% a year).

Where do these Glaxosmithkline Pharmaceuticals figures come from?

From Glaxosmithkline Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.